December 4, 2019 07:26 AM EST
R&D

An old, con­tro­ver­sial Pfiz­er drug shows mid-stage ef­fi­ca­cy against nar­colep­sy

Jason Mast

Editor

Re­box­e­tine nev­er got much trac­tion in the US. Mar­ket­ed as an an­ti-de­pres­sant in Eu­rope for the past 20 years, the Pfiz­er drug was pro­vi­sion­al­ly FDA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times